Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No. 1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, is a ben("Sias") (Head office: Sakyo-ku, Kyoto; Representative Director: Shiro Ozaki), a venture capital company.

Execution of Investment in 0sias
Sias is a regenerative medicine venture that aims to commercialize regenerative T cells (T-iPS cells), which are produced by generating iPS cells from cytotoxic T cells (killer T cells) and then differentiating those iPS cells into T cells, as a therapeutic agent for cancer and infectious diseases.

Essentially, a patient's killer T cells recognize cancer cells and specifically injure them. Adoptive immunotherapy, in which killer T cells are removed from the body, cultured and proliferated, and then transplanted back into the body, is known to exert a high anti-tumor effect. However, existing adoptive immunotherapy has the problem that it is difficult to sufficiently proliferate killer T cells outside the body. With this technology, Sias aims to realize the world's first adoptive immunotherapy using T-iPS cells.

The company has entered into a joint research agreement with the Kaneko Laboratory (Associate Professor Arata Kaneko) of the Center for iPS Cell Research and Application (CiRA), Kyoto University, to license a wide range of T-iPS cell-related technologies based on papers such as "Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and We will continue our research and development while licensing a wide range of T-iPS cell-related technologies based on papers such as "Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation" (Cell Stem Cell).

Kyoto iCAP has recently invested approximately 50 million yen in stock and bonds with stock acquisition rights in recognition of the social significance of the challenge to deliver T-iPS therapy, which utilizes iPS cell technology, one of Kyoto University's most important research achievements, to patients as soon as possible, and in anticipation of the possibility of expanding the application of T-iPS therapy to many types of cancer and non-cancer diseases. In anticipation of the possibility of expanding the application of T-iPS therapy to many types of cancer and diseases other than cancer, we have invested a total of approximately 50 million yen in stocks and bonds with stock acquisition rights.

Outline of Sias Corporation

Establishment	August 24, 2015
Business	Development of therapies for cancer and other diseases using regenerated T cells (TiPS cells)
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Shiro Ozaki